I am 47. Will Capecitabine help manage my breast cancer?

Question

Hello doctor,

I am 47 years old and was diagnosed with metastatic breast cancer eight months ago, after initially being treated for stage 2 disease three years ago. My recent CT scan shows progression in my liver and new lesions in my bones. My tumor markers are rising, CEA is now 45 ng/mL, and CA 27.29 is 78 U/mL.

I am currently on Palbociclib plus Letrozole, but my neutrophil count dropped to 800/μL during the last cycle, and we had to delay treatment. The bone metastases are causing severe pain in my spine and ribs, despite being on Oxycodone 20 milligrams every eight hours. My oncologist mentioned switching to chemotherapy like Capecitabine, but I am terrified of the side effects.

I have a 12-year-old daughter, and I am trying to balance treatment with quality time with her. The fatigue is overwhelming, and I can barely manage household tasks. My liver function tests are slightly elevated, with ALT at 68 U/L.

Should I seek a second opinion about treatment options? Are there clinical trials I should consider? I want to fight this, but I also do not want to spend my remaining time sick from chemotherapy.

How do I make these impossible decisions about balancing quantity versus quality of life?

Please help.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

You have already been through a lot, like a diagnosis of metastatic breast cancer with liver and bone progression, rising tumor markers, and worsening symptoms, despite targeted therapy with Palbociclib and Letrozole.

The drop in your neutrophil count (800/μL) is associated with CDK4/6 (cyclin-dependent kinase 4 and 6) inhibitors like Palbociclib, but it limits their continued use. Add to that the bone pain, fatigue, and impact on daily life, and this is not just about tumor control but about day-to-day living.

Switching to Capecitabine (oral chemotherapy) is a standard and reasonable next step, especially with visceral progression. Many patients tolerate it better than expected, and its oral form will offer convenience compared to IV (intravenous) chemotherapy. Side effects like fatigue, hand-foot syndrome, or GI (gastrointestinal) symptoms can be managed or dose adjusted.

However, given your concerns, it is entirely valid to seek a second opinion, especially at an academic or cancer center where clinical trials are available.

Some options like :

Antibody drug conjugates (example: Sacituzumab govitecan), if your cancer is triple negative or hormone-resistant, then it is a good option.
Targeted therapies such as PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), BRCA mutations (breast cancer gene), and ESR1 (estrogen receptor 1) mutations, depending on tumor profiling.
Bone-modifying agents like Denosumab or Zoledronic acid can reduce bone pain and the risk of fractures.

More importantly, your question about balancing longevity with quality of life is at the heart of metastatic cancer care. Integrating palliative care early can be invaluable, not as “end-of-life” care but as supportive care to help you manage symptoms, preserve function, and make informed choices about what you want from treatment.

You can absolutely continue to fight the disease while prioritizing time, energy, and clarity for the things and people you love.

So yes, a second opinion is appropriate. There will definitely be clinical trials or newer treatments tailored to your cancer’s profile. You do not have to choose between fighting and living well; they can co-exist, with the proper care team helping you weigh options.

I hope this has helped you.

Please feel free to reach out to me again if you have further queries.

Thank you.